Realizing Value With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors-Reference-Cited by-同舟云学术

Realizing Value With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors

Published:2018-08-21 Issue:8 Volume:138 Page:767-769
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Blumenthal Roger S.¹,Nasir Khurram¹²³,Martin Seth S.¹

Affiliation:

1. Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, MD (R.S.B., K.N., S.S.M.)

2. Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT (K.N.)

3. Center for Outcomes Research & Evaluation (CORE), Yale New Haven Health Services Corp, CT (K.N.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference15 articles.

1. Treatment of Cholesterol in 2017

2. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

3. Peck P. FOURIER opens with a bang: big LDL reduction prevents MI but with a price tag. MEDPAGETODAY. March 17 2017. https://www.medpagetoday.com/MeetingCoverage/ACC/63909. Accessed May 1 2018.

4. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy

5. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de los iPCSK9 en la práctica clínica;REC: CardioClinics;2021-01

2. Just Price for PCSK9 Inhibitors: No less, No More;Journal of the American Heart Association;2018-11-06